Description
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
SIMR (Sacramento/Valley Area): Karen Everman evermak@sutterhealth.org
Modesto: Delia Massone MassonD@sutterhealth.org and Adrienne Palos PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals@sutterhealth.org
View study details on ClinicalTrials.gov
Principal Investigator
Co-Investigator(s)
Saunders C. Hsu, M.D, YiSheng Lee, M.D.
Recruitment Status
Active, Not Recruiting
Start Date
February 01, 2019